Anaphylaxis
Aug 13, 2024
FDA Approves Ascendis Pharma’s YORVIPATH; ARS Pharma Gets FDA Green Light for First Nasal Spray; FDA Rejects Lykos’ MDMA-Assisted PTSD Therapy; Novartis’ FABHALTA Receives FDA Accelerated Approval; Servier Snags FDA Approval for Voranigo
Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency Ascendis Pharma A/S has announced that the FDA has approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. YORVIPATH, a prodrug of parathyroid hormone (PTH[1-34]), is adm...
Read More...
Jan 10, 2020
Anaphylaxis: A Rare Disease
Anaphylaxis is a rare disease which can even result in life-threatening situations. Mostly the allergic reaction is due to food, insect stings, medications and latex. Usually, the symptoms are expressed in one part of the body; however, in some instances, the reaction is severe. Sometimes, a specific type ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
